Debut Biotechnology
Debut Biotechnology joined Merck and the lab on the scalable total synthesis of saxitoxin.
San Diego, California
- Papers together
- 1
- Years
- 2025
- Co-authors
- 1
The record
Our paper with Debut Biotechnology
-
Scalable Total Synthesis of Saxitoxin and Related Natural Products
- Merck & Co. Christopher K. Prier, Kai-Jiong Xiao
- Debut Biotechnology Christopher K. Prier
No papers match these filters.
Our co-authors at Debut Biotechnology
Christopher K. Prier
Some of these papers were shared with another partner: Merck & Co..
Keep exploring
More partners
Enamine
HitGen Hongene Biotech Hongene Biotech IKA IKA InduPro Therapeutics InduPro Therapeutics
KULR Technology RQx Pharmaceuticals RQx Pharmaceuticals Socrates Biosciences Socrates Biosciences The Medicines Company The Medicines Company Work with us
Interested in collaborating with the Baran lab?
If your team has a problem that matters, a molecule no one can make, a reaction that will not scale, a reagent that should exist, we would love to hear about it.
Email Philor write to pbaran@scripps.edu